The results revealed that the upregulation of ANGPTL4 and Follistatin were significantly and positively associated with the extent of tumor regression (Figure 5), indicating that these proteins may serve as functional biomarkers linking propranolol exposure to therapeutic response. The gene discussed is ANGPTL4; the disease is neoplasm.